IceCure Medical Ltd (ICCM)
NASDAQ: ICCM · Real-Time Price · USD
1.120
-0.030 (-2.61%)
At close: Dec 20, 2024, 4:00 PM
1.110
-0.010 (-0.89%)
After-hours: Dec 20, 2024, 5:55 PM EST
IceCure Medical Revenue
IceCure Medical had revenue of $662.00K in the quarter ending September 30, 2024, with 102.45% growth. This brings the company's revenue in the last twelve months to $3.67M, up 26.02% year-over-year. In the year 2023, IceCure Medical had annual revenue of $3.23M with 4.67% growth.
Revenue (ttm)
$3.67M
Revenue Growth
+26.02%
P/S Ratio
14.73
Revenue / Employee
$47,675
Employees
77
Market Cap
61.35M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 3.23M | 144.00K | 4.67% |
| Dec 31, 2022 | 3.09M | -1.05M | -25.45% |
| Dec 31, 2021 | 4.14M | 270.00K | 6.98% |
| Dec 31, 2020 | 3.87M | -1.87M | -32.61% |
| Dec 31, 2019 | 5.74M | 1.70M | 42.18% |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
| Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Outset Medical | 114.73M |
| Apyx Medical | 48.54M |
| Cryo-Cell International | 31.84M |
| Forian | 19.71M |
| Verrica Pharmaceuticals | 9.21M |
| VolitionRx | 1.29M |
ICCM News
- 5 days ago - Data on IceCure's ProSense® Cryoablation for Low-Risk Breast Cancer Presented at Radiological Society of North America's 2024 Annual Meeting - PRNewsWire
- 25 days ago - IceCure Medical Ltd (ICCM) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 25 days ago - IceCure Medical Reports 36% Sales Growth in the First Nine Months of 2024 Driven by Global Adoption of ProSense® Cryoablation - PRNewsWire
- 26 days ago - IceCure's Next-Generation Multiprobe Cryoablation Technology Issued Notice of Allowance from Japan's Patent Office - PRNewsWire
- 4 weeks ago - IceCure Medical to Report Third Quarter 2024 Financial & Operational Results on November 26, 2024 - PRNewsWire
- 4 weeks ago - IceCure's ProSense® Chosen for Breast Cryoablation Study Led by the Prestigious European Institute of Oncology with Sponsorship from the Italian Ministry of Health - PRNewsWire
- 6 weeks ago - FDA Advisory Panel Votes in Favor of IceCure's ProSense® Cryoablation Benefit-Risk Profile in Early-Stage Low Risk Breast Cancer - PRNewsWire
- 7 weeks ago - Upcoming FDA Advisory Panel for IceCure's ProSense® Marketing Authorization Receives Large Number of Public Comments from Stakeholders - PRNewsWire